1. Japan Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Delta-Fly Pharma, Inc.

Delta-Fly Pharma, Inc.

TTSE:4598
75.00
JPY
-4.00
(-5.06%)
2.57BMarket Cap
Nov 13Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
209.53
56.15
- -
22.39
65.16
55.38
- -
- -
- -
- -
- -
Basic EPS, GAAP
70.87
-92.19
-170.16
-348.32
-187.34
-178.58
-234.51
-198.78
-195.58
-140.45
- -
Free Cash Flow per Basic Share
-58.5
37.45
-148.3
-372.22
-157.93
-173.61
-230.02
-178.11
-208.48
-134.5
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
213.25
228.15
801.93
456.47
391.14
227.54
124.22
149.78
28.55
2.58
2.58
Tangible Book Value per Share
213.21
228.12
801.91
456.46
391.14
227.54
124.22
149.78
28.55
2.58
2.58
Basic Weighted Avg Shares
4
3
4
4
5
5
6
7
9
12
11
Sales/Revenue/Turnover
902
150
- -
100
300
300
- -
- -
- -
- -
- -
Operating Margin (%)
36.44
-162.55
- -
-1,545.53
-284.08
-320.49
- -
- -
- -
- -
- -
Depreciation Expense
1
1
1
2
2
2
2
2
2
1
- -
Net Income, GAAP
305
-246
-674
-1,556
-863
-967
-1,329
-1,429
-1,721
-1,626
- -
Effective Tax Rate (%)
5.62
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
33.82
-164.18
- -
-1,555.79
-287.53
-322.43
- -
- -
- -
- -
- -
Working Capital
759
803
3,475
2,010
2,033
1,190
751
1,191
238
-5
-5
LT Debt
19
13
6
- -
- -
- -
- -
- -
- -
- -
- -
Total Equity
769
822
3,504
2,056
2,079
1,233
791
1,233
278
34
34
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-30.95
-31.14
-55.96
-41.72
-58.41
-131.28
-141.25
-227.9
-1,043.02
- -

Capital Structure

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
11
12
13
Market Capitalization
7,931
6,177
2,569

Working Capital

JPY

•

in mil. unless spec.
Jun'26
Sep'26
Mar'26
Total Current Assets
- -
469
208
Cash, Cash Equivalents & STI
- -
435
145
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
153
213
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-37.19%
-87.77%
Free Cash Flow
- -
18.86%
-15.13%
Net Income, GAAP
- -
14.39%
-5.53%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-43.07
-48.84
-49.84
-55.47
-198.78
2025
- -
- -
- -
- -
-195.58
2026
- -
- -
- -
- -
-140.45

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Kiyoshi Eshima
Full Time Employees
12
Sector
Health technology
Industry
Pharmaceuticals: major
Address
37-5 Nishikino Tokushima TK Japan 771-0116
IPO Date
Oct 12, 2018
Website
delta-flypharma.co.jp
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Delta-Fly Pharma, Inc. Delta-Fly Pharma, Inc. (4598.T) develops novel anticancer drugs using proprietary module drug development technology that combines existing compounds to enhance safety and efficacy profiles. The company focuses on oncology therapeutics targeting hematologic and solid tumors, with a pipeline including DFP-10917, a nucleoside analog in phase III trials in the United States and phase I in Japan for relapsed/refractory acute myeloid leukemia; DFP-14323, a cancer stem cell regulator in phase III for lung cancer; DFP-17729 in phase I/II for solid cancers; DFP-11207, a cancer cell metabolism regulator that completed phase I for pancreatic cancer and advances in solid tumors; DFP-14927 in phase I for hematologic and solid cancers including gastroesophageal, pancreatic, and colorectal; and DFP-10825 in preclinical stages for gastric and ovarian cancers with peritoneal dissemination. Operations span Japan, Canada, China, and the United States through offices in Tokyo, Beijing, Vancouver, and ongoing international clinical programs; founded in 2010 and headquartered in Tokushima, Japan. Recent developments encompass progress updates on the phase I/II combination study of DFP-10917 with venetoclax for acute myeloid leukemia as of October 2025, advancing phase III trials for DFP-14323 in lung cancer, and multiple pipeline advancements including patient recruitment for combo trials with a mega pharmaceutical partner targeted for new drug application submission.